Document is current
Any future updates will be listed below
-
Authors
Kwatra, Shawn G. https://orcid.org/0000-0003-3736-1515
Khattri, Saakshi
Amin, Ahmad Z.
Ranza, Roberto
Kaplan, Blair
Shi, Linyu
Padilla, Byron
Soliman, Ahmed M.
McGonagle, Dennis
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03675308 at ClinicalTrials.govnct03671148 at ClinicalTrials.govDocuments that mention this clinical trial
POS1024 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 1
https://doi.org/10.1136/annrheumdis-2022-eular.1186
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
https://doi.org/10.1136/rmdopen-2025-005522
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
https://doi.org/10.1007/s40744-025-00793-3
AB0559 EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2678
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
Documents that mention this clinical trial
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
https://doi.org/10.1136/rmdopen-2022-002286
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2695
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
https://doi.org/10.1136/rmdopen-2025-005522
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2
https://doi.org/10.1136/annrheumdis-2022-eular.1673
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
https://doi.org/10.1007/s40744-025-00793-3
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
- License Information
-
More Information
Article History
Received: 31 January 2024
Accepted: 19 April 2024
First Online: 13 May 2024
Declarations
:
: Shawn G. Kwatra is an advisory board member/consultant and/or investigator for AbbVie, Arcutis, ASLAN, Celldex, Galderma, Genzada, Incyte, J&J, Novartis, Pfizer, Regeneron, and Sanofi. Saakshi Khattri is a speaker, serves as an advisory board member for, and/or has received research grants from AbbVie, BMS, Janssen, LEO, Lilly, Novartis, Pfizer, and UCB. Ahmad Z. Amin has received speaker or consulting fees from AbbVie, Amgen, BMS, Dermavant, Incyte, Janssen, LEO, Lilly, Regeneron, Sanofi-Genzyme, Pfizer, and UCB. Roberto Ranza is a consultant for AbbVie, Janssen, Novartis, and Pfizer, and is a member of speaker bureaus for AbbVie, Janssen, Novartis, and Pfizer. Blair Kaplan, Linyu Shi, Byron Padilla, and Ahmed M. Soliman are employees of AbbVie, and may hold AbbVie stock, stock options, and/or patents. Dennis McGonagle has received research grants from and/or is a member of speaker bureaus for AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB.
: The clinical trials were conducted in accordance with the operations manual, protocol, International Council for Harmonisation guidelines, and applicable guidelines and regulations governing ethical principles and study conduct originating in the Declaration of Helsinki. Independent ethics committees/institutional review boards ensured the ethical, scientific, and medical appropriateness of the study before it was conducted and approved all relevant documentation including the protocol, informed consent form(s), and all participant materials. Written informed consent was obtained from all patients before enrollment.
